Eloralintide and tirzepatide combined for weight loss in adults with obesity
Tests eloralintide with tirzepatide for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Key facts
- Where
- Berlin, Bochum, Cologne, Essen, Gladbeck, Hamburg, Leipzig, Lübeck, Offenbach, Oldenburg, and Ratingen, GermanySee the 11 sites
- Phase
- Phase 3
Where in Germany
- FutureMeds BerlinBerlin, GermanyNo longer taking part
- Siteworks GmbH - BochumBochum, GermanyNo longer taking part
- Zentrum fur klinische Forschung - KölnCologne, GermanyNo longer taking part
- InnoDiab Forschung GmbhEssen, GermanyNo longer taking part
- Hausarztzentrum ButendorfGladbeck, GermanyNo longer taking part
- Diabeteszentrum Hamburg WestHamburg, GermanyNo longer taking part
- AmBeNet GmbHLeipzig, GermanyNo longer taking part
- UKSH Campus Lübeck, Med. 1 - AG MeyhöferLübeck, GermanyNo longer taking part
- FutureMeds OffenbachOffenbach, GermanyNo longer taking part
- RED-Institut GmbHOldenburg, GermanyNo longer taking part
- SANOS ClinicRatingen, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881432EU 2026-526047-34-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Inclusion: Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥35 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any glucose-lowering medication within 90 days of screening.